stockportfolio.pro
Stocks / NUVB vs RXRX
NUVB vs RXRX
Nuvation Bio Inc. and Recursion Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Nuvation Bio Inc. (NUVB) | Recursion Pharmaceuticals, Inc. (RXRX) | |
|---|---|---|
| Market cap | $1.6B | $1.6B |
| Revenue (latest FY) | $62.90M | $74.26M |
| Net income (latest FY) | $-204.63M | $-644.76M |
| Revenue growth (5y CAGR) | — | 79.7% |
| Net margin | -325.3% | -868.3% |
| Return on equity | -66.9% | -57.0% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open NUVB — free Open RXRX — freeFrequently asked questions
Which is bigger, NUVB or RXRX?
Nuvation Bio Inc. is larger by market capitalization — $1.6B versus $1.6B.
Which grows faster, NUVB or RXRX?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.